In August 1997, AmBisome (liposomal amphotericin B, Nexstar, San Dimas, CA) was the first drug approved for the treatment of visceral leishmaniasis by the U.S. Food and Drug Administration. The growing recognition of emerging and reemerging infections warrants that safe and effective agents to treat such infections be readily available in the United States. The following discussion of the data submitted in support of the New Drug Application for AmBisome for the treatment of visceral leishmaniasis shows the breadth of data from clinical trials that can be appropriate to support approval for drugs to treat tropical diseases.
In August 1997, AmBisome (liposomal amphotericin B;
the Indian cantonment of Dumdum near Calcutta. Leishman, a pathologist, noted that these patients were distinguished from Nexstar, San Dimas, CA) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of visceral other patients with fever by profound cachexia and unusually large spleens. The microscopic examination of the postmortem leishmaniasis (VL). This is the first drug approved for this indication in the United States. As awareness of the emergence spleen from one such patient revealed many small round bodies. He speculated that these forms were trypanosomes, the descripand reemergence of the more exotic, traditionally tropical diseases grows, so does the need for well-documented evidence tion of which had recently been made by Bruce. Leishman suggested that patients with kala-azar and sleeping sickness of the safety and efficacy of the drugs used to treat these infections. The Division of Special Pathogens and Immunoalso be studied after death for the presence of such round bodies. It is noteworthy that kala-azar, the disease entity delogic Drug Products, FDA, which has regulatory responsibility for all antiparasitic drugs, advises early dialogue in the developscribed by the Hindi expression for darkening of the skin, was a well-described clinical syndrome at the time of Leishman's ment process of drugs for the treatment of tropical diseases. Such discussion can facilitate the submission and review of report. Kala-azar only later came to be known as VL, the infection of major organs caused by parasites of the genus that applications. The subsequent approval process can provide greater access to drugs for the treatment of these infections.
was ultimately named Leishmania. Recent developments in human experience with this genus of parasite have made it a topic of growing interest, which was See editorial response by Berman on pages 49 -51. perhaps most highly publicized by the diagnosis of viscerotropic leishmaniasis in veterans who served in the Persian Gulf Herein, the clinical and microbiological data submitted to in 1991 [2] . In the 1980s, VL became recognized as an opportusupport the approval of AmBisome for the treatment of VL nistic infection in HIV-positive patients in southern Europe. are reviewed. An example of a drug approval that used an To date, ú1,000 such cases have been reported [3] . Epidemics historical control and data from studies conducted outside the of visceral disease have been seen in the Sudan and Brazil in United States is provided. The discussion illustrates the breadth the past decade [4] . A growing number of cases in which there of data from clinical trials that can be utilized to support drug was resistance to the traditional first-line therapy, pentavalent approval and serves as a point from which to offer suggestions antimonials, has been documented in India [5] . about future trial design.
Clinical Considerations Historical Perspective

Diagnosis
In 1903, Leishman [1] reported an account of Dumdum fever, a febrile illness encountered in British soldiers serving in Since the association made by Leishman in the early part of this century, VL has been diagnosed by microscopic visualization of the amastigote stage of the parasite in infected tissues, [4] .
AmBisome was reported in 1991 [12] . Subsequent reported Response to infection is determined in part by the immune studies of other preparations of amphotericin B lipid complexes status of the host. Although the presentation of VL is fairly for the treatment of VL also demonstrated efficacy. Two Amuniform throughout the world, response to treatment is not.
phocil (Sequus Pharmaceuticals, Menlo Park, CA) regimens Reports of resistance to standard treatments such as antimonials evaluated in a small series in Brazil had efficacy rates of 90% -are increasing in parts of Europe, India, and East Africa [4, 6, 100% for previously untreated patients [13] . Low-dose therapy 7]. Because of these variations in tissue tropism, host response, with Abelcet (Liposome Company, Princeton, NJ) for VL paand geography, it is important to carefully define any populatients in India who had had poor responses to pentavalent tion of patients with VL who are to be studied.
antimony was studied; the long-term efficacy rate was 84% -100% [14] . The clinical data that supported the approval of AmBisome for the treatment of VL included a study that summarized the Triangle Park, NC) and meglumine antimonate (Glucantime; Rhône-Poulenc, Antony Cedex, France), has been the mainstay results of four clinical trials in the medical literature [15 -18] and case reports for all patients included in three of these of treatment for VL since its introduction. As experience with these drugs has grown, so has the incidence of treatment failstudies [15 -17] . All of the clinical trials were conducted outside the United States. Three of the trials [15 -17] drug sponsor according to immune status and to the dosing database included 129 patients. The safety database for the entire NDA included ú1,500 patients. regimen that they received. The dosing regimens used for the various cohorts of patients treated in these referral centers are summarized in table 2. The fourth report [18] described a series of patients treated under field conditions in the Sudan. Because
Design of Clinical Trials
these patients had more advanced disease, received different dosing regimens of AmBisome, and had less consistent followSpleen, bone marrow, or liver aspirates were obtained from up than those in the referral centers, the data from the Sudan patients with clinically suspected VL. For patients to be inwere not considered central to the application by the FDA. The cluded in the study, amastigotes had to be visualized in or following discussion of the data supporting the FDA approval cultured from the aspirate. During treatment and follow-up, of AmBisome for the treatment of VL is based on the results weight, temperature, spleen size, routine serum chemistry meaof treatment of patients in Europe and Brazil.
surements, hematologic findings, and erythrocyte sedimentaIt should be noted that treatment of VL was one of several tion rate were recorded at regular intervals. Another aspirate indications being requested in this NDA; therefore, the safety was obtained at the end of therapy for microscopy and culture. database available was larger than the population of patients
The parasite count in the spleen or bone marrow aspirate was with VL who were studied. The other indications for which quantified by the method of Chulay and Bryceson [19] ; this AmBisome was approved were empirical therapy for febrile parasitological end point was considered the test of cure. Folneutropenia and the treatment of aspergillus, candida, and/or low-up visits were scheduled at 1, 3, 6, and 12 months after cryptococcus infection refractory to traditional amphotericin B treatment; at these visits, patients were assessed by clinical examination and repeated laboratory tests. Parasitological studor for patients with renal impairment. For VL, the efficacy / 9c5e$$ja34
12-27-98 17:17:05 cida UC: CID CID 1999;28 (January) U.S. FDA Approval of AmBisome for Treatment of VL ies were done if there were any clinical or laboratory findings with antileishmanial drugs or had treatment §1 month before enrollment in the present trial, had a record of undergoing a suggestive of relapse.
AmBisome therapy for immunocompetent patients infected repeated parasitological study at end of therapy, and were followed up §6 months after treatment. in southern Europe or Brazil was studied. Approximately onethird of these patients' isolates were identified to the species level; all isolates from patients in southern Europe that were Efficacy identified to the species level were L. infantum. Clinical trials began with a dose that was thought adequate to cure. SubseThe analysis of efficacy performed by the drug sponsor used two separate end points: acute clearance of parasites as deterquent cohorts were then treated with progressively lower doses or shorter courses of therapy in an attempt to establish the mined by microscopy and/or culture of spleen or bone marrow aspirates at the end of therapy and overall success, which inlower limit of efficacy. In total, there were six cohorts of immunocompetent patients studied (table 2, cohorts I -VI). The clinicluded those patients with clearance of parasites at the end of therapy who remained relapse-free in the follow-up period 6 -cal trials including immunosuppressed patients enrolled patients infected in the Mediterranean basin, including Europe 12 months after completion of therapy. Failures were defined by parasites in repeated tissue aspirates at the end of therapy and North Africa; because of the high relapse rate among the first cohort, a second, more intensively treated cohort was studand relapses following acute clearance of parasites. The following discussion of the analysis of the clinical trial data for immuied (table 2, cohorts VII and VIII).
nocompetent hosts distinguishes between the drug sponsor and the FDA analyses of these populations. Both analyses are pre-
FDA Approach to Review
sented in table 2.
Immunocompetent patients -drug sponsor analysis. The The combination of the requirement for parasitological idenefficacy rates calculated in the drug sponsor analysis at both tification, the large number of patients studied, and the length the end of therapy and follow-up are presented in table 2; the of time that patients were followed up after treatment made 95% confidence intervals around these point estimates were these studies unusual in the medical literature on drug treatment well within the efficacy rate range of 90% -95% that is exof VL. At the time of the review of the NDA for AmBisome, pected for an effective antileishmanial drug. The drug sponsor there were no drugs approved for use in the United States for defined the success rate as the number of patients who remained the treatment of VL. It was not possible to study the efficacy relapse-free during §6 months of follow-up divided by the of AmBisome in a controlled trial with an approved active number of patients with parasitological clearance at the end of comparator. Untreated, the disease is regarded as ultimately therapy. fatal; therefore, a historical control was invoked. The fatal
Immunocompetent patients -FDA analysis. The use of outcome of untreated disease was considered the initial basis more exclusive evaluability criteria determined by the FDA from which to determine drug effect. For purposes of approval, (see above) identified 87 immunocompetent patients who were it was then necessary to establish the efficacy of the drug(s) clinically and parasitologically evaluable. In the FDA analysis, regarded as the standard of care in the treatment of VL; the failures at 21 days were carried forward and included in the efficacy of AmBisome would then be compared with this stancalculation of the overall success rate. By this scheme, the dard. A review of the literature and personal communications success rate was defined as the number of patients cured at the with experts suggested that the primary response rate associated end of therapy who did not relapse divided by the total number with an effective drug should be 90% -95%.
of evaluable patients. The overall success rate is a more stringent measurement of efficacy. On the basis of these criteria, Results efficacy rates associated with AmBisome as treatment of VL in immunocompetent patients remained in the range expected
Evaluability Criteria
for an effective antileishmanial agent at both the end of therapy and follow-up (table 2) . A total of 108 immunocompetent patients and 21 immunosuppressed patients were enrolled in the study. All patients
The total dose approved for the treatment of VL is 21 mg/kg given on 7 days over a 21-day period. At the end of were considered evaluable by the drug sponsor. Of the immunocompetent patients, Ç65% were children, 56% were male, therapy, the efficacy rate associated with AmBisome as treatment of VL in patients who received §21 mg/kg (cohorts I, and 7% had had prior therapy for VL. Of the immunosuppressed patients, 81% were HIV-positive and 62% had had II, and III) was 100% (33 of 33) in the drug sponsor analysis and 100% (25 of 25) in the more stringent analysis performed prior therapy for VL. A more exclusive analysis of evaluability was performed by the FDA. All case reports for patients in by the FDA. The efficacy rate for these patients at follow-up was 100% (30 of 30) and 100% (25 of 25), respectively. The European and Brazilian centers were reviewed. Patients who were deemed evaluable by the FDA were those who were patients in cohort IV received a total dose of 18 mg/kg. The overall success rates for cohort IV at follow-up were 97.6% infected in the Mediterranean basin, had no prior treatment / 9c5e$$ja34
12-27-98 17:17:05 cida UC: CID (40 of 41) in the sponsor analysis and 97.0% (32 of 33) in the this disease. These data strongly suggest that the immunosuppressed host with VL is not able to achieve the same response FDA analysis. Efficacy was maintained for patients receiving less than the recommended dose in both analyses. Such efficacy with AmBisome therapy in long-term follow-up. It is noteworthy that 81% of the immunosuppressed patients were HIVrates were viewed as supportive of the dosing regimen that was approved.
positive. Those patients coinfected with HIV may represent a special subgroup, and generalization of their responses to therImmunosuppressed patients -drug sponsor and FDA results. The response to treatment in the first cohort of immunoapy for all immunosuppressed patients may not be appropriate. The suggestion has been made that multiple courses of treatsuppressed patients (cohort VII) was characterized by a higher rate of relapse than seen among the immunocompetent patients. ment and/or long-term maintenance therapy may be needed to prevent relapse in the immunocompromised patient [21] . The Because of this finding, a second cohort of immunosuppressed patients was treated with a more intensive regimen (cohort NDA submission did not provide data to support or refute this possibility. VIII). The relapse rate remained high among these patients (table 2) . This finding was noted in both the drug sponsor analysis and the FDA analysis of the results. Although some level of clinical response and clearance of parasites was noted
General Issues in Design of Clinical Trials
for most immunosuppressed patients treated with the abovementioned regimens, the high relapse rates of 80% and 100%
Controlled, prospective clinical trials using FDA-approved comparators are the standard for the evaluation of drugs to are remarkable.
treat infections. For certain circumstances including some tropical and/or parasitic infections, this type of study may not be is known about the efficacy of unapproved comparators such Assessment of relationship to the study drug was not made in as the pentavalent antimonials. A historical control was acceptall cases, but no patient's treatment regimen was changed beable in this indication because it was possible to determine that cause of a clinical adverse event or because of abnormal laborathere was a consensus regarding the acceptable efficacy of an tory findings. One episode of mild arterial hypotension was agent to treat VL and it was possible to quantify and verify reported after the first dose. Rashes, nausea and/or vomiting, parasitological identifications and end points. Despite the lack and headache were observed in three or fewer patients. There of an active concurrent control arm, these studies were larger were no episodes of phlebitis associated with infusion. Review than most reported series evaluating drug therapy for VL and of the larger safety database of ú1,500 patients provided some provided an adequate follow-up interval that would capture comparative safety information on AmBisome and amphoterimost relapses. The availability of case reports for all patients cin B. In some subgroups, AmBisome was associated with in the pivotal studies permitted verification of evaluability and lower levels of nephrotoxicity and fewer episodes of hypokaefficacy data as reported by the applicant. It also permitted a lemia than was amphotericin B.
more stringent analysis of the data that supported the findings of the applicant.
Discussion
For the purpose of FDA approval, it is also possible to conduct active-controlled studies with unapproved compara-
Results of AmBisome Clinical Trials
tors. Such a comparator may be used if it represents the standard of care in the geographic region where the study is being The submitted studies demonstrated the efficacy of AmBisome in the treatment of VL in immunocompetent patients conducted or as established by the peer-reviewed medical literature. It is highly desirable that the choice of comparator be (both adult and pediatric) in the Mediterranean basin who had documented or presumed L. infantum infection. Data supportagreed upon in advance, as should the intent to demonstrate whether the investigational agent is equivalent or superior to ing the clinical efficacy of AmBisome as treatment of VL caused by other species and from other geographic foci were the comparator. The submission of such clinical trial results should be accompanied by literature that supports the choice not provided by this NDA. It is noteworthy that in vitro data do demonstrate activity of AmBisome against L. donovani and of an unapproved comparator. Data from trials conducted outside the United States may be that the medical literature includes reports of the therapeutic use of AmBisome for VL patients in India, where the infection used to support approval by the FDA. The study population should be applicable to the intended patient population in the is generally caused by L. donovani [20] .
The markedly higher relapse rate noted among the immunoUnited States. The requirements of the Declaration of Helsinki must be observed, and informed consent must be obtained suppressed patients with VL warrants some consideration of the host when discussing the efficacy of AmBisome as treatment of and documented. Clinical trial design, conduct, and results are / 9c5e$$ja34 12-27-98 17:17:05 cida UC: CID reviewed for scientific integrity and verifiability, regardless of courses of therapy or of maintenance therapy, clinical studies demonstrating efficacy of such regimens are needed. the location of the study.
The submission of published studies to provide supporting data to a report is one means of providing quantitative data for Conclusion analysis by the medical reviewer. Prior submission of the planned protocol during the Investigational New Drug phase AmBisome is the first drug approved in the United States for is strongly advised if this approach is elected. Early discussion the treatment of VL. Discussion of the nature of the application of clinical trial design with the FDA allows the drug sponsor submitted to support this approval highlights certain important and the medical reviewer to appreciate the goals of a study aspects of clinical trial design that are pertinent to the developand helps to meet the scientific and regulatory requirements of ment of drugs for the treatment of tropical diseases. There a subsequent NDA.
exists a wide range of possibilities in the design of clinical Many of the drugs developed to treat parasitic infections trials to evaluate drugs for the treatment of these often rare may be designated orphan drugs because they are for treatment infections. The Division of Special Pathogens and Immunoof a rare disease. The orphan designation is based on an applicalogic Drug Products, FDA, encourages early dialogue in the ble patent in the United States only. Orphan designation and development of these products to best meet the regulatory reapproval for marketing are two separate processes; the drug quirements to demonstrate drug safety and efficacy. sponsor must apply for each separately. After approval of a drug that has been granted an orphan designation, the FDA
